MUC13 and colitis: Muc13−/− mice seemed to exhibit more severe clinical signs of colitis and macroscopic colonic inflammation than wildtype controls upon acute DSS colitis, whereas an enhanced recovery was noticed after the second cycle of DSS administration (Figure 6A–D).